March 24, 2025 10:57 AM EDT
News Briefing

Sur­rozen rais­es $175M, to fo­cus on oph­thal­mol­o­gy; CBC Group has a new $1B fund

ENDPOINTS

Plus, news about CG On­col­o­gy, Opus Ge­net­ics and Val­ne­va:

Sur­rozen’s piv­ot and cap­i­tal raise: The South San Fran­cis­co drug de­vel­op­er is

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Trump pledges his sup­port for a change to the IRA long sought by drug­mak­ers

J&J's Du­a­to says 'not tar­iffs, but tax pol­i­cy' is best way to boost US man­u­fac­tur­ing

Phar­ma tar­iffs could leave lit­tle room to hide with sweep­ing probe un­der­way

Sanofi’s Kymab-orig­i­nat­ed in­flam­ma­to­ry drug flunks mid-stage asth­ma tri­al

Leqem­bi wins EU au­tho­riza­tion for some Alzheimer's pa­tients, giv­ing Bio­gen, Ei­sai a boost over Lil­ly

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times